TY - JOUR
T1 - Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF.
AU - Jander, Nikolaus
AU - Hochholzer, Willibald
AU - Kaufmann, Beat A
AU - Bahlmann, Edda
AU - Gerdts, Eva
AU - Boman, Kurt
AU - Chambers, John B
AU - Nienaber, Christoph A
AU - Ray, Simon
AU - Rossebo, Anne
AU - Pedersen, Terje R
AU - Wachtell, Kristian
AU - Gohlke-Bärwolf, Christa
AU - Neumann, Franz-Josef
AU - Minners, Jan
PY - 2014/9/12
Y1 - 2014/9/12
N2 - OBJECTIVE: To evaluate the usefulness of velocity ratio (VR) in patients with low gradient severe aortic stenosis (LGSAS) and preserved EF. BACKGROUND: LGSAS despite preserved EF represents a clinically challenging entity. Reliance on mean pressure gradient (MPG) may underestimate stenosis severity as has been reported in the context of paradoxical low flow, LGSAS. On the other hand, grading of stenosis severity by aortic valve area (AVA) may overrate stenosis severity due to erroneous underestimation of LV outflow tract (LVOT) diameter, small body size or inconsistencies in cut-off values for severe stenosis. We hypothesised that VR may have conceptual advantages over MPG and AVA, predict clinical outcomes and thereby be useful in the management of patients with LGSAS. METHODS: Patients from the prospective Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study with an AVA
AB - OBJECTIVE: To evaluate the usefulness of velocity ratio (VR) in patients with low gradient severe aortic stenosis (LGSAS) and preserved EF. BACKGROUND: LGSAS despite preserved EF represents a clinically challenging entity. Reliance on mean pressure gradient (MPG) may underestimate stenosis severity as has been reported in the context of paradoxical low flow, LGSAS. On the other hand, grading of stenosis severity by aortic valve area (AVA) may overrate stenosis severity due to erroneous underestimation of LV outflow tract (LVOT) diameter, small body size or inconsistencies in cut-off values for severe stenosis. We hypothesised that VR may have conceptual advantages over MPG and AVA, predict clinical outcomes and thereby be useful in the management of patients with LGSAS. METHODS: Patients from the prospective Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study with an AVA
U2 - 10.1136/heartjnl-2014-305763
DO - 10.1136/heartjnl-2014-305763
M3 - Article
C2 - 25217488
SN - 1468-201X
JO - Heart (British Cardiac Society)
JF - Heart (British Cardiac Society)
ER -